5 +/- 1.0 mg/dL, and the serum parathyroid hormone (PTH) level was 315 +/- 569 pg/dL. The control group comprised 17 individuals without PHPT. The mean age of controls was 60.8 +/- 12.5 years and the serum calcium concentration was 9.8 +/- 0.3 mg/dL. Motor and sensory nerve conduction was assessed by electroneurography (ENG).
Results: LY2157299 chemical structure The following ENG parameters differed significantly between the PHPT and control groups: right (R) sural
sensory nerve action potential conduction velocity (52.7 +/- 6.3 m/s versus 58.0 +/- 8.0 m/s; P = .041); R median compound muscle action potential (CMAP) amplitude (7.4 +/- 1.6 mV versus 8.9 +/- 1.7 mV; P = .002); R median CMAP latency (4.3 +/- 1.2 ms versus 3.6 +/- 0.6 ms; P = .032); R tibial CMAP latency (4.2 +/- 1.1 ms versus 3.3 +/- 0.4 ms; P = .001). The neurological examination was normal in all patients.
Conclusion: Our data demonstrate an association between PHPT and peripheral neurological CX-5461 price alterations, consistent with subclinical sensory-motor PPN.”
“Objective: To assess the association of sex and age with presenting symptoms and size of vestibular schwannoma at clinical presentation to our clinics.
Study Design: Retrospective chart review.
Setting: Academic medical center.
Patients: Approximately 1,269 subjects diagnosed with unilateral vestibular schwannoma between 1997 and
2010.
Intervention: Demographic information, tumor characteristics, and treatment strategy were recorded.
Main Outcome Measure: Tumor size, patient-reported presence of hearing loss or dizziness at presentation.
Results:
Male subjects had significantly larger tumors than female subjects at presentation (18.23 versus 16.81 mm, p = 0.031); this difference was particularly pronounced in patients younger than 40 years. Patient-reported symptoms at baseline also differed by sex: the prevalence of hearing loss was 95.1% in male subjects versus 90.3% in female subjects (p = 0.001), and the frequency of dizziness was 74.3% in female subjects versus 59.0% in male subjects (p < 0.0001). In multivariate analyses, male subjects continued to find more have a borderline significant positive association with tumor size (p = 0.066) and were 2-fold more likely to have hearing loss (odds ratio [OR], 2.082; 95% confidence interval [CI], 1.300-3.336) but half as likely to have dizziness (OR, 0.501; 95% CI, 0.387-0.649) than female subjects. Additionally, for every 1-mm increase in tumor size, patients were more likely to report hearing loss by 14.7% (OR, 1.147; 95% CI, 1.106-1.191) and dizziness by 2.8% (OR, 1.028; 95% CI, 1.016-1.041).
Conclusion: We observed significant sex differences in the presentation and size of unilateral vestibular schwannomas. As management and treatment strategies are predicated on presenting symptoms and patient factors, these observations merit further study to further understand tumor biology, improve risk stratification, and optimize tumor management.